| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.03 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.03 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.03 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.03 |